BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest Res. 2020;18:151-167. [PMID: 32326669 DOI: 10.5217/ir.2019.09154] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Hartwig O, Shetab Boushehri MA, Shalaby KS, Loretz B, Lamprecht A, Lehr CM. Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. Adv Drug Deliv Rev 2021;175:113828. [PMID: 34157320 DOI: 10.1016/j.addr.2021.113828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
2 Xu X, Lin S, Yang Y, Gong X, Tong J, Li K, Li Y. Histological and ultrastructural changes of the colon in dextran sodium sulfate-induced mouse colitis. Exp Ther Med 2020;20:1987-94. [PMID: 32782508 DOI: 10.3892/etm.2020.8946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yu J, Wang S, Yuan H, Qiao T, Bao M. Expression of Th17/Treg Cells in Peripheral Blood and Related Cytokines of Patients with Ulcerative Colitis of Different Syndrome Types and Correlation with the Disease. Evid Based Complement Alternat Med 2021;2021:4600947. [PMID: 34603468 DOI: 10.1155/2021/4600947] [Reference Citation Analysis]
4 Son M, Park IS, Kim S, Ma HW, Kim JH, Kim TI, Kim WH, Han J, Kim SW, Cheon JH. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function. Front Immunol 2022;13:870817. [PMID: 35693794 DOI: 10.3389/fimmu.2022.870817] [Reference Citation Analysis]
5 Lee JW. Ulcerative Colitis and Patient's Quality of Life, Especially in Early Stage. Gut Liver 2022;16:317-8. [PMID: 35551102 DOI: 10.5009/gnl220181] [Reference Citation Analysis]
6 Eun CS. Intestinal microbiota and inflammatory bowel diseases. J Korean Med Assoc 2021;64:588-95. [DOI: 10.5124/jkma.2021.64.9.588] [Reference Citation Analysis]
7 Robinson AM, Stavely R, Miller S, Eri R, Nurgali K. Mesenchymal stem cell treatment for enteric neuropathy in the Winnie mouse model of spontaneous chronic colitis. Cell Tissue Res 2022. [PMID: 35536444 DOI: 10.1007/s00441-022-03633-w] [Reference Citation Analysis]
8 Yuan X, Chen Y, Tang M, Wei Y, Shi M, Yang Y, Zhou Y, Yang T, Liu J, Liu K, Deng D, Zhang C, Chen L. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs). J Med Chem 2022. [PMID: 35709396 DOI: 10.1021/acs.jmedchem.2c00604] [Reference Citation Analysis]
9 Park MY, Yoon YS, Lee JL, Park SH, Ye BD, Yang SK, Yu CS. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study. Stem Cell Res Ther 2021;12:401. [PMID: 34256838 DOI: 10.1186/s13287-021-02484-6] [Reference Citation Analysis]
10 Zhang C, Qi W, Li Y, Tang M, Yang T, Liu K, Chen Y, Deng D, Xiang M, Chen L. Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem 2021;64:1966-88. [PMID: 33593051 DOI: 10.1021/acs.jmedchem.0c01468] [Reference Citation Analysis]
11 Innocenti T, Bigagli E, Lynch EN, Galli A, Dragoni G. MiRNA-Based Therapies for the Treatment of Inflammatory Bowel Disease: What Are We Still Missing? Inflamm Bowel Dis 2022:izac122. [PMID: 35749310 DOI: 10.1093/ibd/izac122] [Reference Citation Analysis]
12 Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol 2020; 26(28): 3998-4017 [PMID: 32821067 DOI: 10.3748/wjg.v26.i28.3998] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lee C, Hong SN, Kim ER, Chang DK, Kim YH. Epithelial Regeneration Ability of Crohn's Disease Assessed Using Patient-Derived Intestinal Organoids. Int J Mol Sci 2021;22:6013. [PMID: 34199463 DOI: 10.3390/ijms22116013] [Reference Citation Analysis]
14 Ohya S, Matsui M, Kajikuri J, Endo K, Kito H. Increased Interleukin-10 Expression by the Inhibition of Ca2+-Activated K+ Channel KCa3.1 in CD4+CD25+ Regulatory T Cells in the Recovery Phase in an Inflammatory Bowel Disease Mouse Model. J Pharmacol Exp Ther 2021;377:75-85. [PMID: 33504590 DOI: 10.1124/jpet.120.000395] [Reference Citation Analysis]
15 Park IS, Son M, Ma HW, Kim J, Kim DH, Kim SW, Cheon JH. Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice. Intest Res 2021;19:349-53. [PMID: 33120440 DOI: 10.5217/ir.2020.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Negi S, Saini S, Tandel N, Sahu K, Mishra RPN, Tyagi RK. Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice. Cells 2021;10:1847. [PMID: 34440615 DOI: 10.3390/cells10081847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 34409654 DOI: 10.1111/jgh.15667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zou M, Zeng QS, Nie J, Yang JH, Luo ZY, Gan HT. The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe? Front Immunol 2021;12:769167. [PMID: 34956195 DOI: 10.3389/fimmu.2021.769167] [Reference Citation Analysis]
19 Martins KR, Araújo JM, Cruz ÁC, Luiz-Ferreira A. EPIDEMIOLOGIC ASPECTS OF INFLAMMATORY BOWEL DISEASE IN THE WESTERN REGION OF MINAS GERAIS STATE. Arq Gastroenterol 2021;58:377-83. [PMID: 34705974 DOI: 10.1590/S0004-2803.202100000-63] [Reference Citation Analysis]
20 Stiegeler S, Mercurio K, Iancu MA, Corr SC. The Impact of MicroRNAs during Inflammatory Bowel Disease: Effects on the Mucus Layer and Intercellular Junctions for Gut Permeability. Cells 2021;10:3358. [PMID: 34943865 DOI: 10.3390/cells10123358] [Reference Citation Analysis]
21 Annese V. Genetics and epigenetics of IBD. Pharmacol Res 2020;159:104892. [PMID: 32464322 DOI: 10.1016/j.phrs.2020.104892] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
22 Lopez-Santalla M, Garin MI. Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases. Biomedicines 2021;9:1507. [PMID: 34829736 DOI: 10.3390/biomedicines9111507] [Reference Citation Analysis]
23 Ha YJ, Kim HJ, Lee E, Park JH, Park YS, Lee YJ, Kang Y, Yoon H. Subclinical sacroiliitis detected by abdominopelvic computed tomography in Korean patients with Crohn's disease. Korean J Intern Med 2021;36:868-77. [PMID: 32872747 DOI: 10.3904/kjim.2020.199] [Reference Citation Analysis]
24 Chen YH, Shin JY, Wei HM, Lin CC, Yu LCH, Liao WT, Chen DC, Chu CL. Prevention of dextran sulfate sodium-induced mouse colitis by the fungal protein Ling Zhi-8 via promoting the barrier function of intestinal epithelial cells. Food Funct 2021;12:1639-50. [PMID: 33481975 DOI: 10.1039/d0fo02604b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ohashi Y. Class III phosphatidylinositol 3-kinase complex I subunit NRBF2/Atg38 - from cell and structural biology to health and disease. Autophagy 2021;:1-12. [PMID: 33459128 DOI: 10.1080/15548627.2021.1872240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Cereser L, Zancan G, Giovannini I, Cicciò C, Tinazzi I, Variola A, Bramuzzo M, Murru FM, Marino M, Tullio A, De Vita S, Girometti R, Zabotti A. Asymptomatic sacroiliitis detected by magnetic resonance enterography in patients with Crohn's disease: prevalence, association with clinical data, and reliability among radiologists in a multicenter study of adult and pediatric population. Clin Rheumatol 2022. [PMID: 35389115 DOI: 10.1007/s10067-022-06143-w] [Reference Citation Analysis]
27 Foligné B, George F, Standaert A, Garat A, Poiret S, Peucelle V, Ferreira S, Sobry H, Muharram G, Lucau‐danila A, Daniel C. High‐dose dietary supplementation with zinc prevents gut inflammation: Investigation of the role of metallothioneins and beyond by transcriptomic and metagenomic studies. FASEB j 2020;34:12615-33. [DOI: 10.1096/fj.202000562rr] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
29 Casimiro-Garcia A, Allais C, Brennan A, Choi C, Dower G, Farley KA, Fleming M, Flick A, Frisbie RK, Hall J, Hepworth D, Jones H, Knafels JD, Kortum S, Lovering FE, Mathias JP, Mohan S, Morgan PM, Parng C, Parris K, Pullen N, Schlerman F, Stansfield J, Strohbach JW, Vajdos FF, Vincent F, Wang H, Wang X, Webster R, Wright SW. Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1. J Med Chem 2021. [PMID: 34967602 DOI: 10.1021/acs.jmedchem.1c01849] [Reference Citation Analysis]
30 Cordeiro BF, Alves JL, Belo GA, Oliveira ER, Braga MP, da Silva SH, Lemos L, Guimarães JT, Silva R, Rocha RS, Jan G, Le Loir Y, Silva MC, Freitas MQ, Esmerino EA, Gala-García A, Ferreira E, Faria AMC, Cruz AG, Azevedo V, do Carmo FLR. Therapeutic Effects of Probiotic Minas Frescal Cheese on the Attenuation of Ulcerative Colitis in a Murine Model. Front Microbiol 2021;12:623920. [PMID: 33737918 DOI: 10.3389/fmicb.2021.623920] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ahmed M, Metwaly A, Haller D. Modeling microbe-host interaction in the pathogenesis of Crohn's disease. Int J Med Microbiol 2021;311:151489. [PMID: 33676240 DOI: 10.1016/j.ijmm.2021.151489] [Reference Citation Analysis]
32 Lin FJ, Li H, Wu DT, Zhuang QG, Li HB, Geng F, Gan RY. Recent development in zebrafish model for bioactivity and safety evaluation of natural products. Crit Rev Food Sci Nutr 2021;:1-29. [PMID: 34058920 DOI: 10.1080/10408398.2021.1931023] [Reference Citation Analysis]
33 Marinho S, Illanes M, Ávila-Román J, Motilva V, Talero E. Anti-Inflammatory Effects of Rosmarinic Acid-Loaded Nanovesicles in Acute Colitis through Modulation of NLRP3 Inflammasome. Biomolecules 2021;11:162. [PMID: 33530569 DOI: 10.3390/biom11020162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Hartwig O, Loretz B, Nougarede A, Jary D, Sulpice E, Gidrol X, Navarro F, Lehr CM. Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1. J Control Release 2022:S0168-3659(22)00163-8. [PMID: 35339579 DOI: 10.1016/j.jconrel.2022.03.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Park J, Kim DH, Kim S, Ma HW, Park IS, Son M, Kim JH, Shin Y, Kim SW, Cheon JH. Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model. Intest Res 2021;19:478-81. [PMID: 34731563 DOI: 10.5217/ir.2021.00121] [Reference Citation Analysis]
36 Huang W, Deng Z, Lu L, Ouyang Y, Zhong S, Luo T, Fan Y, Zheng L. Polysaccharides from soybean residue fermented by Neurospora crassa alleviate DSS-induced gut barrier damage and microbiota disturbance in mice. Food Funct 2022;13:5739-51. [PMID: 35527507 DOI: 10.1039/d2fo00137c] [Reference Citation Analysis]